hanibaram/iStock via Getty Images
The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.
CAR-T biotech Arcellx (ACLX
U.S. IPO Weekly Recap: The February IPO Market Kicks Off With 2 Biotechs
Summary
- The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.
- CAR-T biotech Arcellx priced at the low end to raise $124 million at a $583 million market cap.
- Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition, which raised $200 million.
Renaissance Capital provides pre-IPO research to institutional investors and investment banks. The Firm manages two IPO-focused funds: The Renaissance IPO ETF (NYSE: IPO) and the Renaissance International IPO ETF (NYSE: IPOS). Individual investors can get a free overview of the IPO market on www.renaissancecapital.com, and try a free trial of our premium platform, IPO Pro (ipopro.renaissancecapital.com). Through Renaissance Capital’s pre-IPO research service, institutional investors get an independent opinion, in-depth fundamental analysis, and customizable financial models on all IPOs.